Revelation Biosciences Statistics
Total Valuation
REVB has a market cap or net worth of $3.30 million. The enterprise value is -$11.25 million.
| Market Cap | 3.30M |
| Enterprise Value | -11.25M |
Important Dates
The last earnings date was Friday, May 10, 2024, after market close.
| Earnings Date | May 10, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
REVB has 1.63 million shares outstanding. The number of shares has increased by 555.96% in one year.
| Shares Outstanding | 1.63M |
| Shares Change (YoY) | +555.96% |
| Shares Change (QoQ) | +376.66% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 1.98% |
| Float | 1.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 7.79 |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.35 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.80, with zero debt.
| Current Ratio | 2.80 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -98.60% and return on invested capital (ROIC) is -94.36%.
| Return on Equity (ROE) | -98.60% |
| Return on Assets (ROA) | -62.70% |
| Return on Capital (ROIC) | -94.36% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$995,654 |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -93.59% in the last 52 weeks. The beta is 0.18, so REVB's price volatility has been lower than the market average.
| Beta (1Y) | 0.18 |
| 52-Week Price Change | -93.59% |
| 50-Day Moving Average | 2.34 |
| 200-Day Moving Average | 12.64 |
| Relative Strength Index (RSI) | 43.14 |
| Average Volume (30 Days) | 152,177 |
Short Selling Information
The latest short interest is 17,742, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 17,742 |
| Short Previous Month | 18,541 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.09% |
| Short Ratio (days to cover) | 0.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.94M |
| Pretax Income | -8.96M |
| Net Income | -8.96M |
| EBITDA | -8.94M |
| EBIT | -8.96M |
| Earnings Per Share (EPS) | -$35.39 |
Balance Sheet
The company has $14.55 million in cash and no debt, giving a net cash position of $14.55 million or $8.91 per share.
| Cash & Cash Equivalents | 14.55M |
| Total Debt | n/a |
| Net Cash | 14.55M |
| Net Cash Per Share | $8.91 |
| Equity / Book Value | 9.47M |
| Book Value Per Share | 5.80 |
| Working Capital | 9.40M |
Cash Flow
In the last 12 months, operating cash flow was -$8.55 million and capital expenditures -$19,172, giving a free cash flow of -$8.57 million.
| Operating Cash Flow | -8.55M |
| Capital Expenditures | -19,172 |
| Free Cash Flow | -8.57M |
| FCF Per Share | -$7.86 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
REVB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -555.96% |
| Shareholder Yield | -555.96% |
| Earnings Yield | -271.66% |
| FCF Yield | -259.76% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 25, 2024. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |